What is virco®TYPE HIV-1?

The virco®TYPE HIV-1 software is intended for use in conjunction with HIV-1 genotyping assays, to calculate drug resistance/susceptibility as an aid in monitoring and treating HIV infection. Specifically, virco®TYPE HIV-1 calculates quantitative levels of phenotypic susceptibility from the HIV genomic sequences corresponding to the HIV protease gene and part of the reverse transcriptase gene.

The virco®TYPE HIV-1 may be used for HIV-1 infected individuals before initial antiretroviral drug therapy as well as for HIV?1 infected individuals with evidence of ongoing viral replication on antiretroviral therapy.

The virco®TYPE HIV-1 result is intended for use in combination with other clinical, treatment, and laboratory factors.
 

What is included in a virco®TYPE HIV-1 report?

The virco®TYPE HIV-1 report combines three layers of HIV-1 resistance information:

  • Genotypic information: the resistance-associated mutations identified in the sample virus are grouped according to drug class (i.e. NNRTI, PI, NRTI, etc.) The patient’s viral genome is compared with a reference virus to determine the presence of any mutations and predict fold changes (FC) based on any mutations present.
  • Mutations associated with resistance are derived from Virco’s correlative database and compared with known mutations in the public domain or identified by sponsors.
  • Phenotypic information: for many HIV/AIDS therapies, the calculated Virtual Phenotype™ fold change (FC) is reported, along with the respective biological or clinical cutoffs. A resistance analysis is provided based on the magnitude of the FC relative to the cut-offs.
  • Additional clinical notes: This section of the report provides complementary information to enhance clinical decision making.
     

The virco®TYPE HIV-1 report consists of three pages:

  • The summary page contains all relevant information to make informed decisions about treatment options or changes that may be required.
  • The second page provides a visual representation of the virus fold changes (FC) along a resistance continuum and includes additional details on the details about the sample.
  • The third page is the definitions and disclaimers page.

To see a virco®TYPE HIV-1 report example, please click here.

Last updated: 29 Mar 2012 15:03:44